1721MO Safety and efficacy of olutasidenib, an IDH1 mutant inhibitor, for the treatment of recurrent/relapsed or locally advanced or metastatic IDH1 mutated chondrosarcoma — Rhonda Jones (2024) | RDL Network
1721MO Safety and efficacy of olutasidenib, an IDH1 mutant inhibitor, for the treatment of recurrent/relapsed or locally advanced or metastatic IDH1 mutated chondrosarcoma
Andrew J. Wagner, Silvia Stacchiotti, C. Debruyne, Abdulazeez Salawu, Jean Yves Blay, Fernando Augusto Batista Campos, Hiroaki Hiraga, Antoine Italiano, Akira Kawai, Ganessan Kichenadasse, Yoshihiro Nishida, Seth M. Pollack, Zhe Qu, Evinaa Sellaiah, Ilona Tala, Gabriel Tinoco, Jonathan C. Trent, Karina Costa Maia Vianna, Kan Yonemori, William D. Tap
Robin L. Jones, Teresa Macarulla, John A. Charlson, Brian Andrew Van Tine, Lipika Goyal, Antoîne Italiano, Christophe Massard, Mark Rosenthal, Macarena I. de la Fuente, Patricia Roxburgh, Madappa N. Kundranda, Jean Yves Blay, Changhoon Yoo, Kate Lipford, Sanjeev Forsyth, Sylvie M. Guichard, Yelena Mikhailov, Blythe Thomson, Patrick Kelly, Florence Duffaud
Melina Verso, Giancarlo Agnelli, Andrés J. Muñoz Martín, Jean M. Connors, Olivier Sanchez, Menno V. Huisman, Benjamin Brenner, Gualberto Gussoni, Alexander T. Cohen, Cecilia Becattini
Paul G. Richardson, Jacob P. Laubach, Sagar Lonial, Philippe Moreau, Sung‐Soo Yoon, Vânia TM Hungria, Meletios A Dimopoulos, Meral Beksaç, Melissa Alsina, Jesús F. San Miguel
Hongjoo J. Lee, Gwang Hun Jeong, H. Li, M S Kim, J S Kim, S J Park, Yi Han, Keum Hwa Lee, Andreas Kronbichler, Seok-Il Hong, Ramy Abou Ghayda, Claudio Luchini, Alessia Nottegar, A Koyanagi, Lee Smith, Linu Abraham Jacob, Elena Dragioti, Joaquim Raduà, Sarah Cargnin, Salvatore Terrazzino, Terry Thompson, Dong Keon Yon,
Discussion(0)
No comments yet. Be the first to comment.